Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbioflor 2 in diarrhoea-predominant irritable bowel syndrome (IBS-D)
2024-512104-19-00Phase 4Authorised
- Sponsor
- Symbiopharm
- Start
- Aug 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Symbioflor 2 with Placebo (2 arms). Primary endpoints: Bristol Stool Scale response rate and Abdominal Pain Intensity response rate (primary definition). Planned start Aug 2024; status: authorised.
02
Drugs
Escherichia coli Symbio DSM 17252
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2024-512104-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512104-19-00.